Navigation Links
EGEN, Inc. Announces that Phase II Clinical Trial for Advanced Ovarian Cancer is Open for Enrollment
Date:12/13/2010

HUNTSVILLE, Ala., Dec. 13, 2010 /PRNewswire/ -- EGEN, Inc. today announced that the first Phase II clinical trial utilizing EGEN-001 for the treatment of recurrent ovarian cancer is now open for enrollment.  The trial is sponsored by the Gynecologic Oncology Group (GOG) under an agreement between the GOG and EGEN, Inc., and is being conducted by a network of researchers led by the GOG at member institutions.  The University of Alabama at Birmingham (UAB) Hospital is the first member institution to open enrollment. Dr. Ronald Alvarez, of UAB Hospital, is the Study Chair for the trial. The GOG Principal Investigator at UAB Hospital is Dr. Mack Barnes.  

"This is a significant milestone and accomplishment for the company," commented Dr. Khursheed Anwer, President and CSO of EGEN. "We are pleased to have this trial begin as it advances our novel EGEN-001 product in the clinic for the treatment of recurrent ovarian cancer.  The product utilizes the Company's proprietary TheraPlas® delivery technology and is composed of interleukin-12 (IL-12) gene formulated with a biocompatible delivery polymer. IL-12 is a potent cytokine which works by enhancing the body's immune system against cancer and inhibiting tumor blood supply.  We expect a number of the leading cancer centers in the U.S. to participate in this study and planning is underway to initiate additional Phase II trials in 2011, including the evaluation of EGEN-001 in treatment of colorectal cancer patients."

About Ovarian Cancer

Ovarian cancer represents the fifth most common form of cancer affecting women and is the most lethal of gynecological malignancies, ranking fourth in cancer deaths among women. The death rate for this disease has not changed much in the last 50 years.  This cancer is often diagnosed at an advanced stage after the cancer has spread beyond the ovary. Over $2 billion is spent in the U. S. each year on treatment of ovarian cancer.

About the Gynecologic Oncology Group

The Gynecologic Oncology Group (GOG) is a not-for-profit organization with the purpose of promoting excellence in the quality and integrity of clinical and basic scientific research in the field of gynecologic malignancies.  The GOG is committed to maintaining the highest standards in clinical trials development, execution, analysis and distribution of results.  The GOG is one of the National Cancer Institute's funded cooperative groups.  The GOG is the only group that focuses its research on women with pelvic malignancies, such as cancer of the ovary, uterus, and cervix.  The GOG is multi-disciplinary in its approach to clinical trials, and includes gynecologic oncologists, medical oncologists, pathologists, radiation oncologists, nurses, statisticians, basic scientists, quality of life experts, data managers, and administrative personnel.

About EGEN, Inc.

EGEN, Inc. (EGEN), with laboratories and headquarters in Huntsville, Alabama is a privately held biopharmaceutical company focused on developing therapeutics for the treatment of human diseases especially cancer. The Company specializes in the delivery of therapeutic nucleic acids (DNA and RNAi) aimed at specific disease targets. The Company has a significant intellectual property position in synthetic carriers, their combination with DNA, expression vectors and their therapeutic applications. EGEN has research pipeline products aimed at treatment of various cancer indications. In addition, the Company has its TheraSilence® delivery technology aimed at delivery of therapeutic siRNA for the treatment of human diseases. EGEN has collaborations with outside investigators, biotech organizations, and universities on various projects in these areas.

Safe Harbor for Forward Looking Statements

Certain statements contained in this press release may be deemed to be forward looking statements under federal securities laws and EGEN intends that such forward looking statements be subject to the safe harbor created thereby.  EGEN does not undertake an obligation to publicly update or revise any forward looking statements, whether as a result of new information, future events or otherwise. Actual events or results may differ from our expectations as a result of a number of factors, including but not limited to uncertainties in clinical trials and product development programs, ability and success level of the Company in securing adequate capital for operations, market place acceptance of any resulting product and other factors common to biotechnology research and development.  There can be no guarantee that any product in our pipeline will be successfully developed.  


'/>"/>
SOURCE EGEN, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... , Feb. 23, 2017 Non-alcoholic ... on the various drugs being developed for ... all the drugs that are in various ... The pipeline focuses on novel pharmacologic drugs ... stem cell therapies, recombinant proteins and RNA-based ...
(Date:2/24/2017)... , Feb 24, 2017 ... Committee,s proposal for a new Board of Directors that ... The 2016-2017 Nomination Committee comprises representatives of the company,s ... quarter of 2016 who have accepted a seat on ... The composition of the 2016-2017 Nomination Committee was as ...
(Date:2/24/2017)... Feb 24, 2017 Research and Markets has ... and Strategies - 2016" report to their offering. ... The latest research Urinary ... data and benchmarks in the global Urinary Incontinence market. The ... are the key drugs marketed for Urinary Incontinence and their clinical ...
Breaking Medicine Technology:
(Date:2/24/2017)... Prior Lake MN (PRWEB) , ... February 24, ... ... the launch of its newly designed TaskMate Go. Core benefits and advantages built ... grain finish and a stylish, functional look and feel. Ability to gain the ...
(Date:2/24/2017)... ... February 24, 2017 , ... WHAT: , ... and recognition opportunities as well as advocacy for the state and region‘s technology ... February 23. The Council's Innovation Forecast event highlights innovation throughout the region ...
(Date:2/24/2017)... ... ... Smart Machine Age is here, and it’s disrupting everything. Not only could it drive ... United States may be taken over by technology in the next five to fifteen ... colleagues is drawing to a close. Success will belong to those who can quiet ...
(Date:2/24/2017)... ... 2017 , ... Healthcare Associates of McKinney announced today that they ... 8080 State Highway 121, Suite 210, McKinney, Texas 75070. It is in the ... As the practice has grown, the need for more space has been paramount. ...
(Date:2/24/2017)... ... February 24, 2017 , ... The California State University Institute for ... engaged in or interested in palliative care education and research. The Symposium, “Innovate. ... North County San Diego on Sept. 28 and 29, 2017, on the campus of ...
Breaking Medicine News(10 mins):